biostudies-literatureOdarenko KVRussian state-funded project for ICBFM SB RASRussian Science Foundation11850https://www.ebi.ac.uk/biostudies/studies/S-EPMC12732811biostudies-literatureUnknown26(24)A disintegrin and metalloproteinase with thrombospondin motifs 6 (ADAMTS6) is an extracellular matrix (ECM) protease that promotes the invasion of lung adenocarcinoma (LUAD) cells. Herein, we investigate its role in epithelial-mesenchymal transition (EMT), a process that drives metastasis and drug resistance in LUAD. Re-analysis of microarray and RNA sequencing data from LUAD cells revealed that during EMT, TGF-β1 increased <i>ADAMTS6</i> expression, presumably through the SMAD pathway, as SMAD2 loss completely blocked this effect. Moreover, <i>ADAMTS6</i> was shown to occupy hub positions within TGF-β1-associated gene networks. Using additional datasets, we found that <i>ADAMTS6</i> expression increased under other EMT-inducing conditions, including IL-1β induction and acquired gefitinib International journal of molecular sciencesDeciphering the Role of ADAMTS6 in the Epithelial-Mesenchymal Transition of Lung Adenocarcinoma Cells.PMC1273281119-74-30011125012300659-6125012300660-2Odarenko KVZenkova MAMarkov AVStepanov GAMatveeva AMfalseDeciphering the Role of ADAMTS6 in the Epithelial-Mesenchymal Transition of Lung Adenocarcinoma Cells.A disintegrin and metalloproteinase with thrombospondin motifs 6 (ADAMTS6) is an extracellular matrix (ECM) protease that promotes the invasion of lung adenocarcinoma (LUAD) cells. Herein, we investigate its role in epithelial-mesenchymal transition (EMT), a process that drives metastasis and drug resistance in LUAD. Re-analysis of microarray and RNA sequencing data from LUAD cells revealed that during EMT, TGF-β1 increased <i>ADAMTS6</i> expression, presumably through the SMAD pathway, as SMAD2 loss completely blocked this effect. Moreover, <i>ADAMTS6</i> was shown to occupy hub positions within TGF-β1-associated gene networks. Using additional datasets, we found that <i>ADAMTS6</i> expression increased under other EMT-inducing conditions, including IL-1β induction and acquired gefitinib 2025-01-01T00:00:00Z2025 Dec2026-05-27T03:14:06.539Z2026-05-27T03:11:16.651ZS-EPMC127328114146527710.3390/ijms262411850